News from calliditas therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

06 Apr, 2020, 07:26 BST Calliditas Appoints New Chief Medical Officer

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that Dr. Richard Philipson has been appointed as Chief Medical Officer (CMO) of...


01 Apr, 2020, 07:14 BST Calliditas Strengthens its US Commercial Organization

Calliditas Therapeutics AB (publ) ("Calliditas") today announced it has strengthened its operations in the United States with the addition of...


30 Mar, 2020, 13:19 BST Calliditas Moves its Annual General Meeting 2020 to June 25

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that due to the recent Covid-19 pandemic, the Company has decided to move its Annual ...


03 Mar, 2020, 12:07 GMT Bulletin From the Extraordinary General Meeting of Calliditas Therapeutics AB (publ)

As part of the preparations for a potential offering of American Depository Shares in the United States and a concurrent listing on the Nasdaq Global ...


14 Feb, 2020, 06:18 GMT Calliditas Therapeutics - Year-End Report 2019

Recruitment for NefIgArd part A completed on plan and budget "In the last quarter of 2019, we achieved a major milestone: the full recruitment of 200 ...


22 Jan, 2020, 07:13 GMT Positive Opinion Received From EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the Treatment of IgAN

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the EMA Paediatric Committee (PDCO) has adopted a positive opinion on the...


09 Jan, 2020, 16:44 GMT Calliditas Submits Draft Registration Statement for the Listing of ADSs in the U.S.

Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") today announces that it has confidentially submitted a draft registration statement ...


23 Dec, 2019, 08:31 GMT The pivotal Phase 3 Clinical Trial NefIgArd Part A Fully Recruited

Calliditas Therapeutics AB (publ) ("Calliditas") today announced the full recruitment of all 200 patients required for Part A of the company's...


19 Dec, 2019, 07:22 GMT Completion of Recruitment of Part A of the Neflgard Pivotal Phase 3 Clinical Trial by Year End

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that 198 out of a total of 200 patients required for Part A of the Company's pivotal ...


17 Dec, 2019, 11:07 GMT China IND Approval Triggers $5 Million Milestone Payment From Everest Medicines

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that a $5 million milestone payment from its partner Everest Medicines II Limited...


14 Nov, 2019, 06:13 GMT Interim Report Q3, 2019

"This third quarter of 2019 saw us move steadily towards full recruitment of the NefIgArd study, despite a somewhat slower pace during the summer...


04 Nov, 2019, 07:21 GMT Calliditas Therapeutics Capital Markets Day Today November 4

Calliditas Therapeutics ("Calliditas") today hosts a Capital Markets Day in Stockholm, moderated by Lars Frick from Börsveckan. The Capital Markets...


01 Oct, 2019, 12:09 BST Save the Date: Calliditas to Host Capital Markets Day in Stockholm on November 4, 2019

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the company will host a Capital Markets Day in Stockholm on November 4, 2019,...


01 Oct, 2019, 07:16 BST Positive Interactions With EMA Provide Route to Conditional Marketing Authorization of Lead Candidate Nefecon

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the European Medicines Agency (EMA) has provided positive guidance related to a ...